This was certainly one of the highlights of my week in Armenia last week. Thank you to Raffy Semerdjian for the opportunity to talk to the Healthcare Executive MBA group at Yerevan State Médical University in my ‘not-so-perfect’ Armenian! It was a blast!
Updates from Haig
CES GOES SOLO, AND SUSTAINABLE
For the first time since the inception of CES, the Detroit Auto show and CES have not gone back to back. For a lot of people, including myself, this yielded a sigh of relief. Firstly we can now stop sharing resources across both shows – challenging given the cross-country distances… Read More »
Do you know if you are offence or defence?
Do you know if you are offence or defence in 2019? As 2019 draws ever closer, whether you’re approaching the new year in attack or defence mode you know that taking no action is not an option. We are working diligently with our clients to strategically prepare for the global… Read More »
Is the U.S. biosimilars market poised for take-off?
Is the U.S. biosimilars market poised for take-off? Read our article and let me know what you think. https://www.pharmasalmanac.com/articles/is-the-u.s.-biosimilars-market-poised-for-takeoff
The evolution of API route decisions
Excited to share Haig Barrett’s latest published article with insights from numerous industry experts – a look at pharmaceutical API route decisions including the increased application of biocatalysts. Check it out – https://www.pharmamanufacturing.com/articles/2019/the-evolution-of-api-route-decisions/ Codexis, Inc. Merck Porton Fine Chemicals Ltd.
Emily Leproust Discusses Synthetic Biology’s Role in Transforming Therapeutics
The rapidly developing field of synthetic biology has the power to revolutionize many industries including chemicals, food, material science, molecular biology, pharmaceuticals, biotherapeutics, and many others. While numerous fields will and are benefiting from synthetic biology advancements, the medical and therapeutics sectors are arguably taking the lead in adopting synthetic… Read More »
Relocation of our HQ to the Dallas Metropole
Thanks to those of you who joined us for the celebrations to mark the first anniversary of the relocation of our HQ to the Dallas Metropole. We were also excited to be launching our new digital marketing transformational group HB2 – which is a unique group of subject matter experts… Read More »
Haig meets Henrikh Mkhitaryan
Was a great pleasure meeting Arsenal and Armenia footballer Henrikh Mkhitaryan at the Armenian comedy event in London this past weekend! Henrikh’s story is rich with inspiration, how his late father’s football career inspires him as a footballer to his visits to the families of those killed in Artsakh. One… Read More »
Engineering Success: Codexis President & CEO Shares Lessons About Corporate Change Management
Given the dynamics of today’s business climate, it might come as no surprise that change management is a topic that emerges constantly as the Haig Barrett team and I interact with executives and executive leadership teams. After years leading the Haig Barrett team to help our clients thrive during periods… Read More »
Behind the Scenes of International Pharmaceutical Business Success: A Conversation with Horst Wallrabe
I grew up in the UK, worked in Belgium and France, and have lived in the United States for more than 22 years. I have a home in Plano, Texas, and in London. To say that much of my life has been spent going back and forth over the ocean… Read More »
Pharma M&A Protecting the Core and Maximizing Value
Article written by Bruce Miles for CPhI North America on behalf of Haig Barrett Inc. and Nice Consulting With a number of mergers and acquisitions taking place in the CRO and CMO/CDMO space, this article highlights several areas driving the success of those new organizations, including: acquisition target criteria, fit with acquiring entity, building management consensus and… Read More »
Perspectives on Drug Product Pricing Strategy and Practice
Originally published on CPhI North America and Haig Barrett Inc. Drug pricing remains pharma’s most contentious issue. Under tremendous pressure, the industry continues to evolve pricing strategy to satisfy intensive regulation, social/political scrutiny and competitive market forces — how other industries face the challenge of pricing may offer fresh insight to fuel an… Read More »